The company has raised a total of $2 million for its first product, TumoCure, designed for solid tumors found in more than 17 million people. CTech
“In 2020, there were 19.3 million new cancer cases worldwide and 10 million deaths, with costs to the healthcare system reaching €199 billion [$217.7 billion] in Europe,” explained Intragel. “Based on 2017–2019 data, nearly 40% of men and women will be diagnosed with cancer during their lifetime, and this global burden is predicted to increase by more than 60%, reaching 29.4 million cases by 2040.”
According to the company, solid tumors affect about 17.4 million patients. Almost one-third of solid tumors (2 million) are inoperable as they are located in areas that can harm vital organs and cause immediate death or metastasis via the lymphatic system. Another 30% of tumors are untreatable due to pre-existing health conditions or they quit the treatment. As a result, 10% of solid cancer patients are inoperable and untreatable. (Photo: IntraGel/Yoav Dudkevitch/Vensica)
“One of the most challenging solid tumors to treat is head and neck cancer (HNC), accounting for 900,000 cases globally,” Intragel continued. “HNC is unique as it is usually an advanced local cancer, meaning it doesn’t develop metastasis very often, making it ideal for surgery or local therapy. However, HNC is a very stubborn cancer, as the recurrence rates after surgery and treatment reach 50%, and, in this case, doctors usually scratch their heads as they consume all available therapies.”
This means no surgery or treatment is possible, and patients are left with palliative treatments without hope of recovering. The company seeks to change this with its gel platform called SRGel, which is both injectable and hydrophobic. This gel platform is designed for sustained drug release which has the potential to replace multiple systemic treatments with a single application. The company expects to pursue a fast-track 505(b)(2) regulatory pathway for head and neck cancer (HNC), which will be its initial indication. Its pipeline could be applied to other cancer types, such as lung, brain, colorectal, ovarian, and testicular cancer. You can learn more about their journey below. Company Name: Intragel Therapeutics
Product/Service description:
Intragel is a pharmaceutical company in the clinical stage that focuses on developing a gel platform called SRGel, which is both injectable and hydrophobic. This gel platform is designed for sustained drug release. SRGel can be easily mixed at room temperature with nearly all anti-cancer drugs, allowing for high drug loading of up to 40%. These drugs can then be injected into solid tumors reachable by biopsy using standard needles. The local application of SRGel and its long-acting properties contribute to an improved quality of life for cancer patients, particularly those who have otherwise untreatable and inoperable forms of cancer. Intragel's first product, TumoCure, combines a concentrated anti-cancer drug that has already demonstrated both safety and efficacy in animal models and clinical use. This product has the potential to replace multiple systemic treatments with a single application. Intragel expects to pursue a fast-track 505(b)(2) regulatory pathway for head and neck cancer, which will be its initial indication. This strategy is anticipated to result in a rapid time-to-market, and Intragel is already in advanced collaboration stages with leading global pharmaceutical companies, opening up possibilities for acquisition. Intragel is currently raising $5 million to get FDA-approved for a phase II clinical trial. Founder Bios:
Peter Siman Ph.D., CEO, and CSO: An enthusiastic entrepreneur with over 15 years of experience in business, pharmaceuticals, chemistry, and materials sciences. Prof. Avi Domb, Co-founder: Has previous experience successfully commercializing an oncology treatment, Gliadel. Avner Geva: Brings experience as a seasoned entrepreneur with more than ten years in the Israeli Medtech/Pharma industry, founded and served as CEO of Vensica Therapeutics. Year of Founding: 2021
Total investment to date: $2 million
Investors (leading and all): Israel Innovation Authority, NGT3VC, NGT II Healthcare, and private investor
Current number of employees: 5
Open positions: N/A
How was the idea born? The creator of Intragel technology is Professor Avi Domb, currently serving as the Chief Scientist of the Ministry of Science and Innovation. Previously, he served as head of the pharmacy school at the Hebrew University of Jerusalem. Prof. Domb is also one of the minds behind the invention of the Gliadel Wafer, which received FDA approval in 2005 as a preventive measure against the recurrence of Glioblastoma (GBM), an extremely aggressive brain tumor, following surgical removal. The Gliadel Wafer is a solid implantable wafer containing the anti-cancer agent Carmustine, strategically placed after GBM resection. The polymer segment of the wafer consists of a naturally occurring fatty acid and a synthetic component, linked together through polyanhydride bonds. Related articles:
Over the past 15 years, Prof. Domb has expanded upon this concept, developing an injectable gel-like polymer with targeting capabilities, simplifying its application to various areas within the human body. His efforts culminated in the creation of a honey-like injectable polymer, composed entirely of naturally occurring fatty acids, ensuring its safety for usage. During the COVID-19 pandemic in mid-2020, Avner Geva, a seasoned entrepreneur, and CEO of the startup Vensica, approached Prof. Domb with the intention of commercializing his technology. Together, they collaborated with the NGT incubator located in Nazareth, an early-stage medical device and life sciences venture capital fund, investing in promising technologies, to advance their idea through an IIA program. The NGT incubator endorsed and facilitated the application submission to the IIA, concurrently appointing a young CEO from the Arab community to lead the company. This strategic move paved the way for a successful funding acquisition in late November 2020. What is the need for the product? In 2020, there were 19.3 million new cancer cases worldwide (WHO) and 10 million deaths, with costs to the Healthcare system reaching €199 billion ($217.7 billion) in Europe (2018). Based on 2017–2019 data, nearly 40% of men and women will be diagnosed with cancer during their lifetime, and this global burden is predicted to increase by more than 60%, reaching 29.4 million cases by 2040. Solid tumors affect about 17.4 million patients. 30% of solid tumors (2 million) are inoperable tumors located in areas that can harm vital organs and cause immediate death or cause metastasis via the lymphatic system. Another 30% are untreatable tumors because the patient would not tolerate the treatment due to their delicate health condition or they quit the treatment. As a result, 10% of solid cancer patients are inoperable and untreatable. One of the most challenging solid tumors to treat is Head and neck cancer (HNC), accounting for 900,000 cases globally. HNC is unique as it is usually an advanced local cancer, meaning it doesn’t develop metastasis very often, making it ideal for surgery or local therapy. However, HNC is a very stubborn cancer, as the recurrence rates after surgery and treatment reach 50%, and, in this case, doctors usually scratch their heads as they consume all available therapies. Hence, no surgery nor treatment is possible, and patients are left with palliative treatments without hope of recovering. On the other hand, immunotherapy has not proven to be effective on HNC, limiting patients' and doctors' options. How is it changing the market? In response to the need for new formulations that enable higher drug loading, long-action, and local release of the drug instead of systemic dispersion to diminish side effects and improve efficacy, IntraGel has developed SRGel. TumoCure will benefit and impact the healthcare system, oncologists, and patients by offering the following USPs:
Easy to use: Injectable gel stable in a single syringe with no need for preheating or manipulation, ready to be placed in any tumor, including surgically inaccessible tumors and/or chemo/radio-resistant tumors. High drug loading: The hydrophobic and solvent-free composition of SRgel allows up to 50% w/w drug loading. A single dose of TumoCure can replace four courses of systemic chemotherapy. Long-lasting release: Biodegradable SRGel starts drug releasing during the first 24 hours, and continues to release the drug at a steady rate over the period of two months after administration. High drug concentration at tumor site: Once injected, SRGel sticks and releases the drug where it was injected at concentrations 100-1000 times higher than through systemic administration. Highly efficient: Preclinical data showed 98% tumor reduction and 80% tumor disappearance. Clinical data clearly showed 35% tumor necrosis after just one month of treatment in a compassionate use of an unresectable, radio, and chemoresistant carcinoma. Safe: Minimal to no systemic toxicity of cisplatin. Solvent-free. Our technology is highly scalable as it can be combined with other anticancer drugs such as paclitaxel, which has already been successfully incorporated in SRGel with promising preclinical results, and other drugs (doxorubicin, paclitaxel, peptides, and proteins) boosting their effectivity and safety. Our pipeline has other cancer types, such as lung, brain, colorectal, ovarian, and testicular cancer. How big is the market for the product and who are its main customers? The SRGel platform and TumoCure belong to the solid tumors market valued at €209 billion ($228 billion) in 2021 and expected to reach €901 billion ($985 billion) by 2029 (CAGR of 20%, 2022-2029). It includes therapies such as chemotherapy, targeted therapy, and immunotherapy. The SRGel Serviceable Available Market (SAM) was estimated based on the 50% of patients with solid tumors challenging to treat with the standard therapies, either chemotherapy or surgery. More than 8.6 million patients annually would benefit from our injectable formulation - a combination of SRGel and an antitumor drug - once we expand it to other tumor indications. Focused on Head and Neck cancer with an incidence of 900,000 cases worldwide, our first indication will target an initial market of €11.3 billion ($12.3 billion). Due to the lack of HNC treatment, we expect an 8% market penetration of TumoCure by 2030 (5 years after the project, three years after approval). Within the project, once we finish TumoCure Ph2 trial, we expect to attract interest in our SRGel platform for other indications and have the first license revenue of SRGel. Does the product exist already? If not - at what stage is it and when is it expected to hit the market? Intragel, a company in the clinical stage, is currently conducting a Phase Ib study in Israel at Hadassah Ein Kerem and Galilee Medical Center in Nahariya. The company has plans to expand its reach by adding more centers to its study by the end of the third quarter of this year. This expansion is in line with Intragel's significant investment in establishing a production facility for both preclinical and clinical studies of SRGel and TumoCure (Gel-Cisplatin). Notably, TumoCure has demonstrated its safety and efficacy in reducing tumor size and impeding growth in both animal and human subjects. A major milestone achieved by our team is bringing TumoCure into the clinical stage and successfully implementing compassionate use in a human patient, resulting in over 35% necrosis in a substantial 200cc tumor after just one month. These accomplishments assisted Intragel to gain considerable momentum and have attracted interest from global pharmaceutical companies for the testing of the SRGel and TumoCure platform to address their specific requirements. These collaborative efforts are progressing and Intragel anticipates their maturation by the first quarter of 2024. In order to enhance these partnerships, enable large-scale production, and pave the way for upcoming clinical investigations, Intragel has secured approval from the Ministry of Health for the conceptual design of expansive production facilities. Finally, we anticipate reaching the market with FDA clearance in 4-5 years as Intragel follows the fast track in FDA, 505(b)(2). Who are the main competitors in this sector and how big are they? We identify this market as a blue ocean with low competition at the market level. Only a few players are at an advanced stage and they target different market segments. There is huge demand and an untapped need with a whole set of customers and end-users willing to pay to solve their problems and obtain the mentioned gains for every actor within the value chain. The market experience of Jelmyto and Zoladex is more advanced than ours, helping us to open the doors to alternative local chemotherapy and to implement an evidence-based pricing strategy. Targeting unmet need and orphan diseases (neglected diseases) in the pharma industry is a competitive strategy because it is an empty niche, and the regulatory roadmap resumes the pathway to commercialization. IntraGel will be the reference partner to develop localized long-acting chemotherapy treatments for all types of solid tumors. SRGel has overcome the challenges of delivering oncology drugs effectively directly into solid tumors, allowing, for the first time, 90% drug concentration at the tumor site and limiting systemic side effects while controlling drug release. SRGel will be the base for optimizing over 95% of current chemotherapeutic agents and supporting new drug developments. What is the added value that the founders bring to the company and the product? Our team of highly professional and experienced scientists and business executives has a proven track record of being able to initiate clinical trials only two years after the launch of IntraGel. This success has attracted pharmaceutical companies. Dr. Peter Siman, CEO & CSO, is an enthusiastic entrepreneur with over 15 years of experience in business, pharmaceuticals, chemistry & materials sciences. Prof. Avi Domb, has previous successful experience commercializing an oncology treatment, Gliadel. Avner Geva, brings experience as a seasoned entrepreneur with more than 10 years in the Israeli MedTech/pharmaceutical industry. What will the money raised during the current investment round be used for? Intragel is aiming to raise $5 million in funding, intended to bolster FDA IND enabling studies, facilitate the establishment of the GMP facility (with Ministry of Health-approved conceptual design), and crucially, advance towards the completion of Phase II clinical trials. In the "Startup Boarding Pass" section, CTech will cover the (relatively) small investments made in companies during the early stages of their existence - and the entrepreneurs and startups who have not yet had the opportunity to reveal their stories to the world. Please use the linked form and fill it out according to the guidelines. This form is intended for startups raising between $500,000 and $3 million from venture capital funds, angels, or official grants from Israeli and foreign institutions. If relevant, someone at CTech will be in touch for follow-up questions. TAGS

Intragel hopes to treat the 10% of inoperable cancer patients

News provided by
Share this article
Share this article
LONDON, Feb. 15, 2023 /PRNewswire/ -- Data Bridge Market Research Published Latest Bladder Disorders Market  Study by in-depth analysis about current scenario, the Market size, demand, growth pattern, trends, and forecast. This report on the study considers important factors such as an analysis of the market, a definition of the market, market segmentation, significant trends in the industry, an examination of the competitive landscape, and research methodology. The top notch Bladder Disorders market research report provides estimations about the growth rate and the market value based on market dynamics and growth inducing factors. While preparing this market analysis report, few of the attributes that have been adopted include highest level of spirit, practical solutions, committed research and analysis, innovation, integrated approaches, and most up-to-date technology. The report offers wide-ranging statistical analysis of the market's continuous developments, capacity, production, production value, cost/profit, supply/demand and import/export. The winning Bladder Disorders market report also assesses the growth rate and the market value based on market dynamics and growth inducing factors. Global bladder disorders market is expected to grow in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.4% in the forecast period of 2022 to 2029 and is expected to reach USD 22,342.48 million by 2029. Download PDF Sample of Bladder Disorders Market @  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bladder-disorders-market
Bladder related disorders include cystitis - inflammation of the bladder, often from an infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer. Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures. Bladder disorders are a group of disorders that can affect human life's daily activity. Some of the most common bladder disorders are cystitis- in which the bladder is infected and causes inflammation. Urinary incontinence- loss of bladder control, interstitial cystitis- bladder pain and frequent, urgent urination, and the overactive bladder- a condition in which the bladder squeezes urine. Bladder disorders can affect the quality of life and cause other health problems. Health changes and issues, including nervous system and lifestyle factors, can cause or contribute to UI in men and women. The Bladder Disorders Market is dominated by Firms Such as:
Medtronic
Market Development:
In August 2021, Vensica Therapeutics Ltd and wMerz Therapeutics announced that they have entered into a collaboration agreement and strategic license for the delivery of botulinum neurotoxin A (Xeomin) to the bladder wall by using Vensica's innovative ultrasound-assisted delivery catheter
In March 2022, Urovant Sciences declared positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory study of URO-902. It is an investigational, novel, locally injected gene therapy product that is used in those patients with overactive bladder (OAB), who did not respond well to oral therapies. These results suggest that URO-902 could deliver new treatment for patients with overactive bladder who have been inadequately respond by oral pharmacologic therapy
In June 2021, Taiho Pharmaceutical has developed, TAC-302 which is a medicine in Phase II development. This medication is orally works and accessible by supporting neurite outgrowth activity in cultured peripheral neurons to cure overactive bladder. The introduction of this new innovative treatment choices will increase patient uptake, which will fuel the expansion of the market
In December 2019, Johnson & Johnson announced the acquisition with TARIS Biomedical LLC Company, a private limited biotechnology corporation that produces high-quality new and innovative drug delivery procedures for the treatment of bladder disorders, including cancer. The TAR-200 is a leading clinical-stage product of the business which used in the patented TARIS System. This silicone-based drug delivery system allows constant drug release into the bladder. The financial details of transactions are not being publicly disclosed. Get Full PDF Research Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-bladder-disorders-market
Opportunities
SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners. Bladder disorder management now places a strong emphasis on assisting patients with a range of alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism. Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes. RISING DISEASE MANAGEMENT PROGRAMS
People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems and increasing healthcare expenditures has encouraged better healthcare plans. Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people. Bladder Disorders Market Scope
View Detailed Research on Bladder Disorders Market @ https://www.databridgemarketresearch.com/reports/global-bladder-disorders-market
Bladder Disorders Market Regional Analysis/Insights
The bladder disorders market report is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above
Countries covered in this market are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of the Middle East and Africa. North America dominates the global bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and growing R&D investments and the launch of novel therapies are boosting the market
A comprehensive analysis will be provided covering the following points in the report:
Executive Market Summary
Explore DBMR Comprehensive Coverage on Healthcare Domain:
Europe Bladder Disorders Market , By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail) - Industry Trends and Forecast to 2029. https://www.databridgemarketresearch.com/reports/europe-bladder-disorders-market
Asia-Pacific Bladder Disorders Market , By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail) - Industry Trends and Forecast to 2029. https://www.databridgemarketresearch.com/reports/asia-pacific-bladder-disorders-market
Middle East and Africa Bladder Disorders Market , By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail) - Industry Trends and Forecast to 2029. https://www.databridgemarketresearch.com/reports/middle-east-and-africa-bladder-disorders-market
North America Bladder Disorders Market , By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail) - Industry Trends and Forecast to 2029. https://www.databridgemarketresearch.com/reports/north-america-bladder-disorders-market
Rise in Incidence of Chronic Diseases Drive the Demand for Bladder Disorder Market - Press Release: https://www.databridgemarketresearch.com/press-release/global-bladder-disorders-market
Overactive Bladder Treatment Market , By Pharmacotherapy (Anticholinergics, Solifenacin, Oxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium and Others), Disease Type (Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-overactive-bladder-treatment-market
Bladder Cancer Treatment Market , By Type (Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Others), Grade Type (Low-grade Bladder Tumor, High-grade Bladder Tumor, Others), Treatment (Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, Others), Route of Administration (Oral, Parenteral, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-bladder-cancer-treatment-market
Non-Muscle Invasive Bladder Cancer Market , By Stage (Ta, Tis, T1), Treatment Class (Chemotherapy, Immunotherapy, Surgery, Radiation Therapy, Intravescial Therapy), Malignant Potential (Low-Grade Tumours, High-Grade Tumours), End-User (Hospitals, Specialized Clinics, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-non-muscle-invasive-bladder-cancer-market
Neurogenic Bladder Infections Market , By Type (Overactive, Underactive), Drug Type (Sulphonamides, Azoles and Amphotericin B, Tetracycline, Nitrofurans, Aminoglycoside Antibiotics, Cephalosporin, Quinolones, Penicillin and Combinations), Test Type (Biochemical Urinary Tract Infection, Microscopic Urinary Tract Infection, Flow Cytometric Urinary Tract Infection), Distribution Channel (Hospital Pharmacies, Gynecology and Urology Clinics, Drug Store, Retail Pharmacies, Online Drug Stores) https://www.databridgemarketresearch.com/reports/global-neurogenic-bladder-infections-market
Pediatric Bladder Treatment Market , By Type (Diurnal Incontinence, Enuresis, Others), Treatment (Urotherapy, Medication, Surgical Reconstruction, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) https://www.databridgemarketresearch.com/reports/global-paediatric-bladder-treatment-market
Bladder Cancer Therapeutics Market , By Type (Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, Others), End-Users (Hospitals, Specialty Clinics, Others), Treatment (Surgery, Chemotherapy, Immunotherapy Radiation Therapy, Others), Major Tests (Cytoscopy, Biopsy, Urinalysis, Urine Cytology and Bladder Ultrasound) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) https://www.databridgemarketresearch.com/reports/global-bladder-cancer-therapeutics-market
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research  is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market. Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. "Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve." Contact:

20:30 ET
Bladder Disorders Market to Exhibit a Remarkable Development of USD 22,342.48 Million by 2029, Size, Share, Trends, Ris...

Vensica Therapeutics is a urology therapeutics and clinical stage biopharmaceutical company. Vensica Therapeutics has closed a $19 million investment round. Vensica executed a strategic collaboration agreement with Merz Therapeutics in 2021 and the Merz Group is participating in Vensica’s financing with up to $3 million, bringing the total round to up to $19 million. The […]

Merz Therapeutics Takes a Bet on Vensica Therapeutics

News provided by
Share this article
Share this article
NEW YORK, Feb. 10, 2022 /PRNewswire/ -- As per Persistence Market Research's latest industry analysis, the global botulinum toxin market recorded market value of US$ 5.1 Bn in 2020, and is projected to expand at a CAGR of 6.9% over the forecast period of 2021-2031. Persistence Market Research Logo
Botulinum toxin (onabotulinumtoxina) is a type of neurotoxin that is produced by the bacteria clostridium botulinum. The toxin comes in two forms - type A and type B. This toxin can be used for the treatment of muscle stiffness or spasms, migraine, hyperhidrosis, over reactive bladder, sialorrhea, and also for cosmetic use such as for skin wrinkles, forehead lines, crow's feet, frown lines, dermal fillers, and more. The post-pandemic period experienced something called as the 'zoom-boom', wherein, most working professionals were constantly using applications for video conferencing such as Zoom, Google Meet, etc., which led them to become more aware about their looks. As such, cosmetic procedures such as Botox treatment, dermal fillers, and others experienced high demand. ·  For instance, according to the Aesthetic Society, the U.S. population spent more than US$ 9 Bn on plastic surgery in the year 2020. Frequent approvals of various botulinum toxin products also leads to the cost-effective availability of these products in the market for consumers to choose from. This, in turn, led to growing demand for all kinds of Botox procedures around the world. Therapeutic procedures done using botulinum toxins are non-invasive, which makes them most sought-after. For instance, in July 2020, Allergan PLC announced FDA approval of its product BOTOX®, a supplemental Biologics License Application (sBLA) for the treatment of muscle spasticity in the lower limbs in pediatric patients above 2 years of age who suffer from cerebral palsy. Request for sample copy of report: https://www.persistencemarketresearch.com/samples/22990
Key Takeaways from Market Study
Botulinum toxin A, which can be used for various therapeutic as well as cosmetic dermatological procedures, leads the botulinum toxin market by capturing more than 98% share. Therapeutic uses of this neurotoxin, such as prevention of migraine, and treatment of hyperhidrosis, sialorrhea, over reactive bladder, and muscle spasticity, are more popular than the cosmetic uses of the toxin, and thus, hold more than half of the total market share. Specialty clinics are preferred more than hospitals, spas, or beauty clinics to undergo Botox procedures, and are expected to project a CAGR of 6.9% over the forecast period. Nearly 60% of the global market share is accounted for by the North American region. Get customized report as per requirement: https://www.persistencemarketresearch.com/request-customization/22990
"Increased application of botulinum toxins for therapeutic and aesthetic purposes will propel market growth over the next few years," says an analyst of Persistence Market Research. Market Competition
Key suppliers of botulinum toxin are focusing on forming strategic partnerships for marketing of their products, gaining approvals from various regulatory authorities around the world, and expanding their portfolios for gaining market foothold. Merz Therapeutics collaborated with Teijin Pharma Ltd, in June 2021, for the marketing of Xeomin®, an incobotulinumtoxinA. In August 2021, it collaborated with Vensica Therapeutics for the innovation of needleless administration of botulinum neurotoxin for the management of over reactive bladder. Get full access of report: https://www.persistencemarketresearch.com/checkout/22990
What Does the Report Cover? Persistence Market Research offers a unique perspective and actionable insights on the botulinum toxin market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031. The research study is based on the product (type A and type B), application (cosmetics (crow's feet, forehead lines, frawn lines/glabellar, square jaw/masseter, and others) and therapeutics (chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis and others)), and end user (hospitals, specialty clinics, and spa & beauty clinics), across seven key regions of the world. Related Reports:
About Persistence Market Research:
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches. Overview:
Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies'/clients' shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part. Contact

06:00 ET
Botulinum Toxin Market is set to expand at a CAGR of 6.9%, and reach a valuation of US$ 10.7 Bn by 2031

Vensica Closes $19 Million Round with Investment from Strategic Partner Merz
Vensica Therapeutics,  a clinical stage biopharmaceutical company, has closed a $19 million investment round. Vensica executed  a strategic collaboration agreement with Merz Therapeutics  in 2021 and the Merz Group is participating in Vensica’s financing with up to $3 million, bringing the total round to up to $19 million. The round was led by Israel Biotech Fund (IBF) with the participation of Laborie, Lew Pell, Agriline, and The Trendlines Group. Merz Therapeutics, a business of the Merz Group, is a leader in the field of neurotoxins. Vensica has exclusively licensed Merz’s botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures. Vensica is unlocking the potential of neurotoxins in urology by developing minimally invasive solutions using the unique properties of therapeutic ultrasound to deliver botulinum toxin A to the bladder. Vensica’s needle-free drug delivery platform is intended for the treatment of urological indications including overactive bladder, neurogenic bladder, and interstitial cystitis. Today’s gold standard treatment requires needle injections of the neurotoxin into the bladder wall. Vensica’s needle-free platform is expected to enable a far superior patient experience resolving needle-associated issues including pain, and urinary retention, making a generally more complicated procedure easier. Vensica’s platform is anticipated to facilitate more efficacious treatment through more uniform delivery of the neurotoxin to the bladder wall. The funds raised will support the company’s phase II multicenter clinical trials in Europe and the USA. Vensica is expanding its workforce in Israel for next stage clinical and regulatory development of its device together with Merz Therapeutics’ XEOMIN®, focusing on overactive bladder treatment. Vensica CEO Avner Geva, commented,
This investment demonstrates Merz’s commitment to us as a company and to establishing a urology treatment platform to treat bladder indications. Merz is the second strategic global company joining this round, following Laborie, a global urology company, that has made two investments in Vensica. Our ambition is to grow and to expand our product portfolio with more solutions that help us to create better outcomes for more patients,
 
states Stefan Brinkmann, CEO of Merz Therapeutics. Merz’ commitment to Vensica reflects how promising the needless treatment of patients with overactive bladder is in combination with our strategic product XEOMIN®. The first months of our collaboration with Vensica already showed good progress and our further investment will strengthen our position as a strategic partner of Vensica and a driver for the development of a less invasive treatment of bladder diseases.

Vensica Closes $19 Million Round with Investment from Strategic Partner Merz

Merz Therapeutics is a global, family-owned aesthetics and neurotoxin company. Driven by the opportunity to help people look better, feel better and live better, Merz earns the confidence of clinicians in aesthetics and neuroscience with a relentless focus on customer service to providers and overall satisfaction for patients.

Merz Therapeutics

Stefan Brinkmann , CEO Merz Therapeutics : `` This strategic , long-term partnership with Vensica allows us to expand into the attractive market of overactive bladder .

Vensica Therapeutics Inks Strategic Partnership with Merz

MitrAssist

MValve Technologies

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B - II

Vensica Therapeutics is a medical device company focused on the urology therapeutics sector. The company develops minimally invasive solutions using therapeutic ultrasound to deliver Botulinum Toxin A for the treatment of various bladder conditions, and is also working on improving bladder cancer treatment. Its primary market includes patients suffering from Overactive Bladder, Neurogenic Bladder, and Painful Bladder Syndrome. It was founded in 2014 and is based in Misgav, Israel.

Name	Avner Geva
Work History	MitrAssist, and MValve Technologies
Title	Founder, Chief Executive Officer
Status	Current

Wells Fargo Success Story

Professional Services

Platform Overview

Vensica Therapeutics

Executives

Vensica Therapeutics Management Team

1 Team Member